CFTR and cystic fibrosis: The most frequent mutation among CF patients, F508del, causes multiple defects that can nevertheless be overcome by a combination of three pharmacological agents that improve CFTR channel trafficking and gating, namely elexacaftor, tezacaftor, and ivacaftor [13].